Malonylated glycerolipids from the glandular trichome exudate of Ceratotheca triloba.

Chemical investigation of the glandular trichome exudate from Ceratotheca triloba (Pedaliaceae) led to the identification of nine 1-O-acetyl-2-O-[(R)-3-acetyloxy-fatty acyl]-3-O-malonylglycerols. Among these, 1-O-acetyl-2-O-[(R)-3-acetyloxyicosanoyl]-3-O-malonylglycerol (7) was the most abundant constituent (41%), followed by 1-O-acetyl-2-O-[(R)-(3-acetyloxyoctadecanoyl)-3-O-malonylglycerol (2; 21%). Compounds having iso- and anteiso-type structures in the 3-acetyloxy-fatty acyl groups in the fatty acyl moiety were also characterized as minor constituents.

The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.

Blocking the binding of TNF-alpha to TNF receptor subtype-1 (TNFR1) is an important strategy for the treatment of rheumatoid arthritis (RA). We recently succeeded in developing a TNFR1-selective antagonistic TNF mutant, R1antTNF. Here, we report the anti-inflammatory effects of R1antTNF in a murine collagen-induced arthritis model.

The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models.

Tumor necrosis factor-alpha (TNF-alpha) is critically involved in a wide variety of inflammatory pathologies, such as hepatitis, via the TNF receptor-1 (TNFR1). To develop TNFR1-targeted anti-inflammatory drugs, we have already succeeded in creating a TNFR1-selective antagonistic mutant TNF-alpha (R1antTNF) and shown that R1antTNF efficiently inhibits TNF-alpha/TNFR1-mediated biological activity in vitro. In this study, we examined the therapeutic effect of R1antTNF in acute hepatitis using two independent experimental models, induced by carbon tetrachloride (CCl(4)) or concanavalin A (ConA).

Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.

Tumor necrosis factor-alpha (TNF) induces inflammatory response predominantly through the TNF receptor-1 (TNFR1). Thus, blocking the binding of TNF to TNFR1 is an important strategy for the treatment of many inflammatory diseases, such as hepatitis and rheumatoid arthritis. In this study, we identified a TNFR1-selective antagonistic mutant TNF from a phage library displaying structural human TNF variants in which each one of the six amino acid residues at the receptor-binding site (amino acids at positions 84-89) was replaced with other amino acids.

Creation of novel cell-penetrating peptides for intracellular drug delivery using systematic phage display technology originated from Tat transduction domain.

Many biologically active proteins need to be delivered intracellularly to exert their therapeutic action inside the cytoplasm. Cell penetrating peptides (CPPs) have been developed to efficiently deliver a wide variety of cargo in a fully biological active form into a range of cell types for the treatment of multiple preclinical disease models. To further develop this methodology, we established a systematic approach to identify novel CPPs using phage display technology.